Seattle Genetics, Astellas ADC heading for bladder cancer submission

Seattle Genetics and Astellas plan to seek accelerated approval of antibody-drug conjugate enfortumab vedotin based on data from the pivotal Phase II EV-201 trial to treat bladder cancer.

Interim results showed that among

Read the full 327 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE